AI assistant
Sending…
Protara Therapeutics, Inc. — Director's Dealing 2020
Aug 20, 2020
34057_dirs_2020-08-20_0de46a0b-5ec0-4c2b-92a4-4071c9db528b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-08-18
Reporting Person: Marshall Randall (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-18 | Common Stock | S | 200 | $25.19 | Disposed | 608732 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.11 to $25.28, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4.
More from Protara Therapeutics, Inc.
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 13
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Mar 30
Regulatory Filings
2026
Feb 24
Regulatory Filings
2026
Feb 2
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27